Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life

Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two ye...

Full description

Saved in:
Bibliographic Details
Published in:Gastroenterology research and practice 2009-01, Vol.2009 (2009), p.1-9
Main Authors: Jeppesen, P. B., Lund, P., Gottschalck, I. B., Nielsen, H. B., Holst, Jens Juul, Mortensen, J., Poulsen, Steen Seier, Quistorff, B., Mortensen, P. B.
Format: Article
Language:English
Subjects:
Clinical Study
Dosage and administration
Drug therapy
Glucagon
Health aspects
Malabsorption syndromes
Management
Patient compliance
Patient outcomes
Quality of life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a556t-b90e18f9885913d9579cc4736f7f4db8d4e8facc765542ac80573d509affcb63
cites cdi_FETCH-LOGICAL-a556t-b90e18f9885913d9579cc4736f7f4db8d4e8facc765542ac80573d509affcb63
container_end_page 9
container_issue 2009
container_start_page 1
container_title Gastroenterology research and practice
container_volume 2009
creator Jeppesen, P. B.
Lund, P.
Gottschalck, I. B.
Nielsen, H. B.
Holst, Jens Juul
Mortensen, J.
Poulsen, Steen Seier
Quistorff, B.
Mortensen, P. B.
description Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment. One had a fibrostenotic lesion electively resected at the jejuno-ascendo-anastomosis. The investigator excluded a patient due to unreliable feedback. Stoma nipple enlargement was seen in all 9 jejunostomy patients. Reported GLP-2 compliance was excellent (>93%). GLP-2 improved the overall quality of life VAS-score (4.1±2.8 cm versus 6.0±2.4 cm, P
doi_str_mv 10.1155/2009/425759
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_669af1ecb1d44596b8f053b863017be7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A233964116</galeid><doaj_id>oai_doaj_org_article_669af1ecb1d44596b8f053b863017be7</doaj_id><sourcerecordid>A233964116</sourcerecordid><originalsourceid>FETCH-LOGICAL-a556t-b90e18f9885913d9579cc4736f7f4db8d4e8facc765542ac80573d509affcb63</originalsourceid><addsrcrecordid>eNqFks9v0zAUxyMEYmNw4gyyxIFfC7Pj2I45II1qlEmVKFoPcLIc57l1SePiJFS984fjkLIxLpxs2R9_3vNXL0keE_yGEMbOMozlWZ4xweSd5JjwQqSc4i93_-xJRo6SB227xphHlt1PjohkEgvKj5OfVysfOvTe76BGc905aLoWLQLoDipkfUCLnUdfQYcW7Vy3QtO6N3rpm3TmvgGaw7ZzFaAMvZjO5mn2Er1FE7_Z1k43Bk7RlbbQ7U-Rbip0YS2YKPcN-tzr2nV75C2aOQsPk3tW1y08OqwnyeLDxWLyMZ19ml5OzmepZox3aSkxkMLKomCS0EoyIY3J4zessHlVFlUOhdXGCM5YnmlTYCZoxbDU1pqS05PkctRWXq_VNriNDnvltVO_D3xYKh06Z2pQnMdHBExJqjxnkpeFxYyWRQyWiBJEdL0bXdu-3EBlYmxB17ekt28at1JL_0NlAnMpiih4fhAE_72HtlMb1xqoa92A71slKKWcSTmUevYPufZ9aGJQigiCM0YJlzfUUsf-XWN9LGsGpzrPKJU8J2SI4PVImeDbNoC97phgNUyTGqZJjdMU6ad_f_KGPYxPBF6NwMo1ld65_9iejDBEBKy-hnNBMszpL5hy2FA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710253169</pqid></control><display><type>article</type><title>Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life</title><source>Open Access: PubMed Central</source><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Jeppesen, P. B. ; Lund, P. ; Gottschalck, I. B. ; Nielsen, H. B. ; Holst, Jens Juul ; Mortensen, J. ; Poulsen, Steen Seier ; Quistorff, B. ; Mortensen, P. B.</creator><contributor>Geboes, Karel</contributor><creatorcontrib>Jeppesen, P. B. ; Lund, P. ; Gottschalck, I. B. ; Nielsen, H. B. ; Holst, Jens Juul ; Mortensen, J. ; Poulsen, Steen Seier ; Quistorff, B. ; Mortensen, P. B. ; Geboes, Karel</creatorcontrib><description>Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment. One had a fibrostenotic lesion electively resected at the jejuno-ascendo-anastomosis. The investigator excluded a patient due to unreliable feedback. Stoma nipple enlargement was seen in all 9 jejunostomy patients. Reported GLP-2 compliance was excellent (&gt;93%). GLP-2 improved the overall quality of life VAS-score (4.1±2.8 cm versus 6.0±2.4 cm, P&lt;.01), the overall SIP score (10.3±8.9% versus 6.2±9.5%, P&lt;.001), the mental component of the SF-36 (45±13% versus 53±11%, P&lt;.05), and the overall IBDQ score (5.1±0.9 versus 5.4±0.9, P&lt;.007) in the 8 patients completing the study. Conclusions. Long-term treatment with GLP-2 is feasible in SBS patients, although caution must be exercised in patients with a history of abdominal pain. Although conclusions cannot be made in a noncontrolled trial, the high reported compliance might reflect a high treatment satisfaction, where the clinical benefits of GLP-2 may outweigh the discomforts of injections.</description><identifier>ISSN: 1687-6121</identifier><identifier>EISSN: 1687-630X</identifier><identifier>DOI: 10.1155/2009/425759</identifier><identifier>PMID: 19590736</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Clinical Study ; Dosage and administration ; Drug therapy ; Glucagon ; Health aspects ; Malabsorption syndromes ; Management ; Patient compliance ; Patient outcomes ; Quality of life</subject><ispartof>Gastroenterology research and practice, 2009-01, Vol.2009 (2009), p.1-9</ispartof><rights>Copyright © 2009</rights><rights>COPYRIGHT 2009 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2009 This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2009 P. B. Jeppesen et al. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a556t-b90e18f9885913d9579cc4736f7f4db8d4e8facc765542ac80573d509affcb63</citedby><cites>FETCH-LOGICAL-a556t-b90e18f9885913d9579cc4736f7f4db8d4e8facc765542ac80573d509affcb63</cites><orcidid>0000-0001-8320-5703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1710253169/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1710253169?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19590736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Geboes, Karel</contributor><creatorcontrib>Jeppesen, P. B.</creatorcontrib><creatorcontrib>Lund, P.</creatorcontrib><creatorcontrib>Gottschalck, I. B.</creatorcontrib><creatorcontrib>Nielsen, H. B.</creatorcontrib><creatorcontrib>Holst, Jens Juul</creatorcontrib><creatorcontrib>Mortensen, J.</creatorcontrib><creatorcontrib>Poulsen, Steen Seier</creatorcontrib><creatorcontrib>Quistorff, B.</creatorcontrib><creatorcontrib>Mortensen, P. B.</creatorcontrib><title>Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life</title><title>Gastroenterology research and practice</title><addtitle>Gastroenterol Res Pract</addtitle><description>Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment. One had a fibrostenotic lesion electively resected at the jejuno-ascendo-anastomosis. The investigator excluded a patient due to unreliable feedback. Stoma nipple enlargement was seen in all 9 jejunostomy patients. Reported GLP-2 compliance was excellent (&gt;93%). GLP-2 improved the overall quality of life VAS-score (4.1±2.8 cm versus 6.0±2.4 cm, P&lt;.01), the overall SIP score (10.3±8.9% versus 6.2±9.5%, P&lt;.001), the mental component of the SF-36 (45±13% versus 53±11%, P&lt;.05), and the overall IBDQ score (5.1±0.9 versus 5.4±0.9, P&lt;.007) in the 8 patients completing the study. Conclusions. Long-term treatment with GLP-2 is feasible in SBS patients, although caution must be exercised in patients with a history of abdominal pain. Although conclusions cannot be made in a noncontrolled trial, the high reported compliance might reflect a high treatment satisfaction, where the clinical benefits of GLP-2 may outweigh the discomforts of injections.</description><subject>Clinical Study</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Glucagon</subject><subject>Health aspects</subject><subject>Malabsorption syndromes</subject><subject>Management</subject><subject>Patient compliance</subject><subject>Patient outcomes</subject><subject>Quality of life</subject><issn>1687-6121</issn><issn>1687-630X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFks9v0zAUxyMEYmNw4gyyxIFfC7Pj2I45II1qlEmVKFoPcLIc57l1SePiJFS984fjkLIxLpxs2R9_3vNXL0keE_yGEMbOMozlWZ4xweSd5JjwQqSc4i93_-xJRo6SB227xphHlt1PjohkEgvKj5OfVysfOvTe76BGc905aLoWLQLoDipkfUCLnUdfQYcW7Vy3QtO6N3rpm3TmvgGaw7ZzFaAMvZjO5mn2Er1FE7_Z1k43Bk7RlbbQ7U-Rbip0YS2YKPcN-tzr2nV75C2aOQsPk3tW1y08OqwnyeLDxWLyMZ19ml5OzmepZox3aSkxkMLKomCS0EoyIY3J4zessHlVFlUOhdXGCM5YnmlTYCZoxbDU1pqS05PkctRWXq_VNriNDnvltVO_D3xYKh06Z2pQnMdHBExJqjxnkpeFxYyWRQyWiBJEdL0bXdu-3EBlYmxB17ekt28at1JL_0NlAnMpiih4fhAE_72HtlMb1xqoa92A71slKKWcSTmUevYPufZ9aGJQigiCM0YJlzfUUsf-XWN9LGsGpzrPKJU8J2SI4PVImeDbNoC97phgNUyTGqZJjdMU6ad_f_KGPYxPBF6NwMo1ld65_9iejDBEBKy-hnNBMszpL5hy2FA</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Jeppesen, P. B.</creator><creator>Lund, P.</creator><creator>Gottschalck, I. B.</creator><creator>Nielsen, H. B.</creator><creator>Holst, Jens Juul</creator><creator>Mortensen, J.</creator><creator>Poulsen, Steen Seier</creator><creator>Quistorff, B.</creator><creator>Mortensen, P. B.</creator><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8320-5703</orcidid></search><sort><creationdate>20090101</creationdate><title>Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life</title><author>Jeppesen, P. B. ; Lund, P. ; Gottschalck, I. B. ; Nielsen, H. B. ; Holst, Jens Juul ; Mortensen, J. ; Poulsen, Steen Seier ; Quistorff, B. ; Mortensen, P. B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a556t-b90e18f9885913d9579cc4736f7f4db8d4e8facc765542ac80573d509affcb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Clinical Study</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Glucagon</topic><topic>Health aspects</topic><topic>Malabsorption syndromes</topic><topic>Management</topic><topic>Patient compliance</topic><topic>Patient outcomes</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeppesen, P. B.</creatorcontrib><creatorcontrib>Lund, P.</creatorcontrib><creatorcontrib>Gottschalck, I. B.</creatorcontrib><creatorcontrib>Nielsen, H. B.</creatorcontrib><creatorcontrib>Holst, Jens Juul</creatorcontrib><creatorcontrib>Mortensen, J.</creatorcontrib><creatorcontrib>Poulsen, Steen Seier</creatorcontrib><creatorcontrib>Quistorff, B.</creatorcontrib><creatorcontrib>Mortensen, P. B.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Gastroenterology research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeppesen, P. B.</au><au>Lund, P.</au><au>Gottschalck, I. B.</au><au>Nielsen, H. B.</au><au>Holst, Jens Juul</au><au>Mortensen, J.</au><au>Poulsen, Steen Seier</au><au>Quistorff, B.</au><au>Mortensen, P. B.</au><au>Geboes, Karel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life</atitle><jtitle>Gastroenterology research and practice</jtitle><addtitle>Gastroenterol Res Pract</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>2009</volume><issue>2009</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1687-6121</issn><eissn>1687-630X</eissn><abstract>Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment. One had a fibrostenotic lesion electively resected at the jejuno-ascendo-anastomosis. The investigator excluded a patient due to unreliable feedback. Stoma nipple enlargement was seen in all 9 jejunostomy patients. Reported GLP-2 compliance was excellent (&gt;93%). GLP-2 improved the overall quality of life VAS-score (4.1±2.8 cm versus 6.0±2.4 cm, P&lt;.01), the overall SIP score (10.3±8.9% versus 6.2±9.5%, P&lt;.001), the mental component of the SF-36 (45±13% versus 53±11%, P&lt;.05), and the overall IBDQ score (5.1±0.9 versus 5.4±0.9, P&lt;.007) in the 8 patients completing the study. Conclusions. Long-term treatment with GLP-2 is feasible in SBS patients, although caution must be exercised in patients with a history of abdominal pain. Although conclusions cannot be made in a noncontrolled trial, the high reported compliance might reflect a high treatment satisfaction, where the clinical benefits of GLP-2 may outweigh the discomforts of injections.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>19590736</pmid><doi>10.1155/2009/425759</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-8320-5703</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-6121
ispartof Gastroenterology research and practice, 2009-01, Vol.2009 (2009), p.1-9
issn 1687-6121
1687-630X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_669af1ecb1d44596b8f053b863017be7
source Open Access: PubMed Central; Wiley Online Library Open Access; Publicly Available Content Database
subjects Clinical Study
Dosage and administration
Drug therapy
Glucagon
Health aspects
Malabsorption syndromes
Management
Patient compliance
Patient outcomes
Quality of life
title Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A53%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20Bowel%20Patients%20Treated%20for%20Two%20Years%20with%20Glucagon-Like%20Peptide%202%20(GLP-2)%20:%20Compliance,%20Safety,%20and%20Effects%20on%20Quality%20of%20Life&rft.jtitle=Gastroenterology%20research%20and%20practice&rft.au=Jeppesen,%20P.%20B.&rft.date=2009-01-01&rft.volume=2009&rft.issue=2009&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1687-6121&rft.eissn=1687-630X&rft_id=info:doi/10.1155/2009/425759&rft_dat=%3Cgale_doaj_%3EA233964116%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a556t-b90e18f9885913d9579cc4736f7f4db8d4e8facc765542ac80573d509affcb63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1710253169&rft_id=info:pmid/19590736&rft_galeid=A233964116&rfr_iscdi=true